Clinical trials: Metformin, completed
Diabetes Mellitus, Type 2
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference…
- Trial name
- NCT00118963
- Testing
- Metformin, Insulin BIAsp30 (Novolog 70/30), Repaglinide
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes Mellitus Type 2
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to test the safety and pharmacodynamics of an oral formulation of insulin in subjects with Type 2 Diabetes.
- Trial name
- NCT01889667
- Testing
- ORMD-0801 Dose # 1, ORMD-0801 Dose # 2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oramed, Ltd.
Polycystic Ovary Syndrome
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
Compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their metabolic and reproductive abnormalities treatment…
- Trial name
- NCT02446834
- Testing
- intensive lifestyle intervention, GLP-1 Receptor Agonists, Metformin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%.
- Conditions
- Non-alcoholic Fatty Liver Disease, Liver Fibrosis, Liver Injury
- Trial name
- NCT06244550
- Testing
- Ganwei, Metformin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei City Hospital
Diabetes Mellitus, Type 2
Linagliptin Add-on to Insulin Background Therapy
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
- Trial name
- NCT02897349
- Testing
- linagliptin, background therapy
- Where
- 25 sites in China
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
GIOIA represents a multicenter pragmatic prospective cohort study, aimed at evaluating the effects of SGLT2 inhibitors currently marketed (dapagliflozin, canagliflozin, empagliflozin) on markers of vascular, myocardial and renal…
- Trial name
- GIOIA (NCT03918148)
- Testing
- SGLT-2i, DPP-4i
- Where
- Italy
- Volunteers
- 1,150 people
- Sponsor
- University of Campania Luigi Vanvitelli
Healthy
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablets co-administered with canagliflozin in healthy…
- Trial name
- NCT02851095
- Testing
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01666730
- Testing
- metformin hydrochloride, oxaliplatin, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Case Comprehensive Cancer Center
Healthy Volunteers
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
- Trial name
- NCT07567781
- Testing
- ABBV-722, Midazolam, Metformin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Diabetes Mellitus, Type 2
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus.
- Trial name
- NCT02119819
- Testing
- LY2944876, Exenatide extended-release, Metformin
- Where
- 51 sites in United States, Greece and 4 more
- Volunteers
- 420 people
- Sponsor
- OPKO Health, Inc.
Hyperglycemia
Investigating the Role of the Polyol Pathway in the Central Nervous System
Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of hyperglycemia.
- Trial name
- NCT02272556
- Testing
- Brain MRS during hyperglycemic clamp, Analysis of Metabolites in cerebrospinal fluid
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Yale University
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).
- Trial name
- NCT00103857
- Testing
- Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Comparator: MK0431 100 mg q.d. (q.d. = once daily), Comparator: Metformin 500 mg b.i.d.
- Volunteers
- 1,208 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of the FDC tablets…
- Trial name
- NCT01508195
- Testing
- Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Polycystic Ovary Syndrome
Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic state.
- Trial name
- NCT00283816
- Testing
- Metformin, Oral Contraceptive Pill, Lifestyle Management Program
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Sepsis, Septic Shock
Safety and Feasibility of Metformin for Sepsis Induced AKI
Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit.
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury, Metformin
- Trial name
- NCT05900284
- Testing
- Metformin low dose, Metformin high dose
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Hernando Gomez
Diabetes
Treatment of Latent Autoimmune Diabetes of the Adult
The purpose of the study is to clarify whether patients classified as Latent autoimmune diabetes of the adult (LADA) benefit from early treatment with insulin added to per oral treatment and lifestyle measures.
- Trial name
- LADA (NCT01140438)
- Testing
- metformin+ NPH insulin, metformin + sitagliptin +/- repaglinide
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Norwegian University of Science and Technology
Healthy
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions
The purpose of this study is compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Alpharma with that of 500 mg CLUCOPHAGE® XR Tablets distributed by Bristol-Myers Squibb Company…
- Trial name
- NCT00865748
- Testing
- Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Type 2 Diabetes
Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
- Trial name
- RENALIS (NCT02106104)
- Testing
- Linagliptin 5 mg QD (N=24), Glimepiride 1 mg QD (N=24)
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Amsterdam UMC, location VUmc
Healthy
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and…
- Trial name
- NCT02121509
- Testing
- Linagliptin, Linagliptin/Metformin ER FDC, Metformin ER
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.